Back to top

Research Daily

Mark Vickery

Top Analyst Reports for Edwards Lifesciences, DexCom & Twitter

TROW EW CI DXCM TWTR QSR

Trades from $3

Friday, October 15, 2021

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 12 major stocks, including Edwards Lifesciences Corp. (EW), DexCom, Inc. (DXCM), and Twitter, Inc. (TWTR). These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.

You can see all of today’s research reports here >>>

Shares of Edwards Lifesciences have outperformed the Zacks Medical Instruments industry in the year to date period (+19.1% vs. +6.5%). The Zacks analyst believes that the huge untapped potential in emerging markets will act as a positive catalyst for Edwards Lifesciences. The company is consolidating its foothold across all its operating businesses through strong pipeline development.

Strong adoption of the SAPIEN 3 Ultra platform and the PASCAL system across Europe is another positive. The solid demand for the company’s products used in high-risk surgeries is impressive too. Stiff competition in the THV business, however, continues to ail the company. Persistent forex woes are also a concern.

(You can read the full research report on Edwards Lifesciences here >>>)

DexCom shares have gained +35.7% over the past year against the Zacks Medical Instruments industry’s gain of +6.6%. The Zacks analyst believes that a strong product portfolio, collaborative agreements with several companies and focus on international markets are key catalysts for growth.

DexCom’s Sensor and other revenue arm's contribution, and domestic and international revenue growth were key catalysts in second-quarter 2021. The company made continued advancements with respect to key strategic objectives and ended the quarter with new patient additions. Intensifying competition, entry of new products, reimbursement risks, supply constraints and working capital problems are some of the major concerns.

(You can read the full research report on DexCom here >>>)

Shares of Twitter have lost -10.9% over the past six months against the Zacks Internet Software industry’s loss of -7%, however, things seem to be improving for the company. The Zacks analyst believes that the company’s initiatives to add features and focus on effectively tackling abuse issues are helping it expand its monetized user base.

Twitter is, however, suffering from stiff competition for ad dollars from the likes of Facebook and Google. Rising investments on international expansion, product innovation and marketing & sales are also expected to hurt profitability in the near term.

(You can read the full research report on Twitter here >>>)

Other noteworthy reports we are featuring today include Cigna Corp. (CI), T. Rowe Price Group, Inc. (TROW) and Restaurant Brands International Inc. (QSR).

Mark Vickery
Senior Editor

Note: Sheraz Mian heads the Zacks Equity Research department and is a well-regarded expert of aggregate earnings. He is frequently quoted in the print and electronic media and publishes the weekly Earnings Trends and Earnings Preview reports. If you want an email notification each time Sheraz publishes a new article, please click here>>>

Featured Reports

New Upgrades

New Downgrades